Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Harvard Business School
Merck
Colorcon
McKinsey

Last Updated: May 21, 2022

MORPHABOND ER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Morphabond Er patents expire, and what generic alternatives are available?

Morphabond Er is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-three patent family members in ten countries.

The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Morphabond Er

A generic version of MORPHABOND ER was approved as morphine sulfate by HOSPIRA on May 11th, 1988.

  Try it Free

Paragraph IV (Patent) Challenges for MORPHABOND ER
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MORPHABOND ER Extended-release Tablets morphine sulfate 15 mg, 30 mg, 60 mg and 100 mg 206544 1 2019-01-28

US Patents and Regulatory Information for MORPHABOND ER

MORPHABOND ER is protected by two US patents.

Patents protecting MORPHABOND ER

Pharmaceutical compositions configured to deter dosage form splitting
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Abuse resistant drugs, method of use and method of making
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-001 Oct 2, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-004 Oct 2, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-002 Oct 2, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-004 Oct 2, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-001 Oct 2, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-002 Oct 2, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for MORPHABOND ER

See the table below for patents covering MORPHABOND ER around the world.

Country Patent Number Title Estimated Expiration
Mexico 336789 FARMACOS RESISTENTES AL ABUSO, METODO DE USO Y METODO DE FABRICACION. (ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING.) See Plans and Pricing
Japan 5965583 See Plans and Pricing
Australia 2009282376 Pharmaceutical compositions configured to deter dosage form splitting See Plans and Pricing
Canada 2923102 MEDICAMENTS RESISTANT AUX ABUS, PROCEDES D'UTILISATION ET DE FABRICATION (ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING) See Plans and Pricing
Australia 2008286914 Abuse resistant drugs, method of use and method of making See Plans and Pricing
Australia 2015200009 Abuse resistant drugs, method of use and method of making See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Medtronic
McKesson
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.